SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid ...
SELLAS Life Sciences Group climbs higher after a premarket drop, reversing course as investors seem to react to new trial‑related updates.
The company said that 72 out of the prespecified 80 deaths required to trigger the final analysis have now occurred as of Dec ...
Detailed price information for Sellas Life Sciences Group Inc (SLS-Q) from The Globe and Mail including charting and trades.
As of Friday, January 02, SELLAS Life Sciences Group, Inc.’s SLS share price has surged by 23.08%, which has investors ...
$SLS insiders have traded $SLS stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales. Here’s a ...
SELLAS Life Sciences (NASDAQ:SLS) said Thursday it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. Shares -32.3% at ...